Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

NCT01339039 is registered in ClinicalTrials.gov with Patrick Y. Wen, MD as lead sponsor.

NCT NCT01339039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01339039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Lead sponsor
Patrick Y. Wen, MD
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2011
Completion date
April 8, 2017
Enrollment
26 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma (aa), anaplastic oligodendroglioma (ao), high grade glioma: glioblastoma (gbm), high grade glioma: gliosarcoma, mixed anaplastic oligoastrocytoma (aoa)